Bleomycin in testicular teratomas.
Bleomycin and its combinations have a definite place in the treatment of metastatic testicular carcinomas other than seminomas and may also prove to be effective, when given as adjuvant postoperative therapy in state II disease. A study, using the combination of Bleomycin and CCNU in 17 patients with metastatic testicular teratoma, is reported. A remission rate of 59% has been observed. Only patients with a complete remission had a satisfactory remission duration. Sequential combinations, using all drugs effective in this disease, may be the most promising way to further improve therapeutic results in terms of remission rate and survival.
D000328:Adult; D001761:Bleomycin / Q000627:therapeutic use*; D002822:Choriocarcinoma / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009362:Neoplasm Metastasis; D012075:Remission, Spontaneous; D013724:Teratoma / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D014750:Vincristine; D008130:Lomustine